Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-12-2011 | Original Paper

RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration

Authors: Peng-Jin Mei, Jin Bai, Hui Liu, Chen Li, Yong-Ping Wu, Zheng-Quan Yu, Jun-Nian Zheng

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2011

Abstract

Purpose

The aim of this study is to investigate whether the expression of RUNX3 is related to the development of glioma, and the role of RUNX3 in glioma cells growth, invasion and migration.

Methods

We analyzed the protein expression of RUNX3 by immunohistochemistry in 188 glioma tissues, 8 normal brain tissues and 8 tumor adjacent normal brain tissues using tissue microarray technique. We studied whether RUNX3 restoration can suppress glioma cells growth, invasion and migration by performing MTT cell proliferation assay, matrigel cell invasion assay, wound-healing assay and migration assay. We also detected MMP-2 protein expression and enzyme activity by western blot analysis and gelatin zymography.

Results

We found that RUNX3 expression was decreased in benign tumor and malignant tumor compared with tumor adjacent normal brain tissue (P < 0.01 and P < 0.05, respectively). We did not find any correlation between RUNX3 expression and clinicopathological parameters. In addition, we demonstrated that re-expression of RUNX3 in glioma cells resulted in significantly inhibited cell invasion and migration abilities. This reduced cell invasion and migration abilities were due to MMP-2 protein expression and enzyme activity suppression after RUNX3 restoration.

Conclusions

Our data indicated that RUNX3 expression is significantly decreased in human glioma, and targeting of the RUNX3 pathway may constitute a potential treatment modality for glioma.

Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA (2008) Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 7:94. doi:10.1186/1476-4598-7-94 PubMedCrossRef

Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD, Dinh DH, Rao JS (2011) MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One 6(6):e20614. doi:10.1371/journal.pone.0020614 PubMed

Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian runt domain. Gene 159(2):245–248PubMedCrossRef

Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, Zhou J, Li G (2010) JWA regulates melanoma metastasis by integrin alpha V beta 3 signaling. Oncogene 29(8):1227–1237. doi:10.1038/onc.2009.408 PubMedCrossRef

Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A (2009) Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19(3):163–170. doi:10.1016/j.semradonc.2009.02.004 PubMedCrossRef

Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85(5):683–693PubMedCrossRef

Cha HJ, Bae SK, Lee HY, Lee OH, Sato H, Seiki M, Park BC, Kim KW (1996) Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 56(10):2281–2284PubMed

Eng C, Herman JG, Baylin SB (2000) A bird’s eye view of global methylation. Nat Genet 24(2):101–102. doi:10.1038/72730 PubMedCrossRef

Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, Li M (2011) Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer. doi:10.1002/ijc.26049

Ichimura K, Vogazianou AP, Liu L, Pearson DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP (2008) 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27(14):2097–2108. doi:10.1038/sj.onc.1210848 PubMedCrossRef

Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H, Ito Y (2008) RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14(3):226–237. doi:10.1016/j.ccr.2008.08.004 PubMedCrossRef

Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS (2005) Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102(5):1454–1459. doi:10.1073/pnas.0409121102 PubMedCrossRef

Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84(4):479–484. doi:10.1038/labinvest.37000603700060 PubMedCrossRef

Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y, Bae SC (2005) RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65(20):9347–9354. doi:10.1158/0008-5472.CAN-05-1647 PubMedCrossRef

Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG (2004) Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23(40):6736–6742. doi:10.1038/sj.onc.12077311207731 PubMedCrossRef

Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66(13):6512–6520. doi:10.1158/0008-5472.CAN-06-0369 PubMedCrossRef

Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109(1):113–124PubMedCrossRef

Lund AH, van Lohuizen M (2002) RUNX: a trilogy of cancer genes. Cancer Cell 1(3):213–215PubMedCrossRef

Merk BC, Owens JL, Lopes MB, Silva CM, Hussaini IM (2011) STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer 11:184. doi:10.1186/1471-2407-11-184 PubMedCrossRef

Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26(4):583–593. doi:10.1038/sj.onc.1209805 PubMedCrossRef

Pennison M, Pasche B (2007) Targeting transforming growth factor-beta signaling. Curr Opin Oncol 19(6):579–585. doi:10.1097/CCO.0b013e3282f0ad0e00001622-200711000-00007 PubMedCrossRef

Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB (1985) Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82(1):119–123PubMedCrossRef

Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T, Mori M (2006) Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15(1):129–135PubMed

Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236. doi:10.3322/caac.20121 PubMedCrossRef

Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796(2):315–331. doi:10.1016/j.bbcan.2009.07.004 PubMed

Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T (2004) Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 23(13):2401–2407. doi:10.1038/sj.onc.12073951207395 PubMedCrossRef

Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68(14):5955–5964. doi:10.1158/0008-5472.CAN-07-5973 PubMedCrossRef

Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, Yang RB, Hong TM, Yang PC (2011) SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene 30(34):3682–3693. doi:10.1038/onc.2011.85

Xiao WH, Liu WW (2004) Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 10(3):376–380PubMed

Zhang Z, Chen G, Cheng Y, Martinka M, Li G (2011) Prognostic significance of RUNX3 expression in human melanoma. Cancer 117(12):2719–2727. doi:10.1002/cncr.25838 PubMedCrossRef

Title: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration
Authors: Peng-Jin Mei
Jin Bai
Hui Liu
Chen Li
Yong-Ping Wu
Zheng-Quan Yu
Jun-Nian Zheng
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1063-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2011

Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells

Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis

Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials

Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer

The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials